Uncertainty-Aware Multimodal Learning via Conformal Shapley Intervals

Multimodal learning combines information from multiple data modalities to improve predictive performance. However, modalities often contribute unequally and in a data dependent way, making it unclear which data modalities are genuinely informative and to what extent their contributions can be trusted. Quantifying modality level importance together with uncertainty is therefore central to interpretable and reliable multimodal learning. We introduce conformal Shapley intervals, a framework that combines Shapley values with conformal inference to construct uncertainty-aware importance intervals for each modality. Building on these intervals, we propose a modality selection procedure with a provable optimality guarantee: conditional on the observed features, the selected subset of modalities achieves performance close to that of the optimal subset. We demonstrate the effectiveness of our approach on multiple datasets, showing that it provides meaningful uncertainty quantification and strong predictive performance while relying on only a small number of informative modalities.

A Random Interaction Forest for Prioritizing Predictive Biomarkers

Precision medicine is becoming a focus in medical research recently, as its implementation brings values to all stakeholders in the healthcare system. Various statistical methodologies have been developed tackling problems in different aspects of this field, e.g., assessing treatment heterogeneity, identifying patient subgroups, or building treatment decision models. However, there is a lack of new tools devoted to selecting and prioritizing predictive biomarkers. We propose a novel tree-based ensemble method, random interaction forest (RIF), to generate predictive importance scores and prioritize candidate biomarkers for constructing refined treatment decision models. RIF was evaluated by comparing with the conventional random forest and univariable regression methods and showed favorable properties under various simulation scenarios. We applied the proposed RIF method to a biomarker dataset from two phase III clinical trials of bezlotoxumab on $\textit{Clostridium difficile}$ infection recurrence and obtained biologically meaningful results.